Daraxonrasib Pancreatic Cancer Pill Doubles Survival

Original Article by Andrew Gregory | The Guardian | 4 May 2026

Daraxonrasib Pancreatic Cancer Pill nearly doubled survival in metastatic PDAC, beating second-line chemo with fewer discontinuations.

Daraxonrasib Pancreatic Cancer Pill nearly doubled survival in metastatic PDAC, beating second-line chemo with fewer discontinuations.

Subscription Required

You must be a subscriber to access all of this content.

View Subscriptions

Already a subscriber? Log in here